Rozanolixizumab Maintains Efficacy Among Generalized Myasthenia Gravis Subgroups

(MedPage Today) -- PHOENIX – Across subgroups, patients who had their generalized myasthenia gravis (gMG) treated with rozanolixizumab (Rystiggo) maintained their responses through multiples cycles of treatment, based on extension data from...
Source: MedPage Today Neurology - Category: Neurology Source Type: news